2010
DOI: 10.1056/nejmoa0908127
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Dutasteride on the Risk of Prostate Cancer

Abstract: Over the course of the 4-year study period, dutasteride reduced the risk of incident prostate cancer detected on biopsy and improved the outcomes related to benign prostatic hyperplasia. (ClinicalTrials.gov number, NCT00056407.)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

36
756
6
19

Year Published

2010
2010
2015
2015

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 1,052 publications
(830 citation statements)
references
References 18 publications
36
756
6
19
Order By: Relevance
“…A similar finding was observed in the REDUCE trial [31]. An obvious inference is that 5-alpha reductase inhibitors may be beneficial in men on surveillance.…”
Section: Role Of 5-alpha Reductase Inhibitorssupporting
confidence: 79%
“…A similar finding was observed in the REDUCE trial [31]. An obvious inference is that 5-alpha reductase inhibitors may be beneficial in men on surveillance.…”
Section: Role Of 5-alpha Reductase Inhibitorssupporting
confidence: 79%
“…More importantly, the downstream signaling pathways of androgen may also crosstalk with each other, making the contributions of androgen to prostate carcinogenesis more complicated. Nonetheless, recent development of more potent antiandrogens and inhibitors of androgen metabolism, which are in clinical trials (138)(139)(140), will aid in understanding the role of androgen signaling in prostate cancer cells. Taken together, better understanding of AR action is likely to lead to better clinical treatments for prostate cancer.…”
Section: Discussionmentioning
confidence: 99%
“…In "the Prostate Cancer Prevention Trial" (PCPT), men treated with the 5α-reductase inhibitor finasteride, which prevents the conversion of testosterone to 5α-dihydrotestosterone, exhibited a 25% reduction in the overall rate of prostate cancer diagnosis [30]. Similarly, in "the Reduction by Dutasteride of Prostate Cancer Events study" (REDUCE), men treated with dutasteride, also a 5α-reductase inhibitor, exhibited a 23% overall relative risk reduction for prostate cancer [31].…”
Section: Discussionmentioning
confidence: 99%